The Latest Cardiac and Vascular News
IRVINE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced follow-up results of the first 230 patients enrolled in its FLASH study. FLASH […]
Represents Largest Catheter Based Thromboaspiration Study Completed to Date LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, announced the safety and efficacy results from the Registry of AngioVac* System Procedures In Detail (RAPID) database. Results […]
Novel angioplasty enhancement system successfully used to restore blood-flow in calcified and fibrous vessels. PARK CITY, Utah, Nov. 12, 2020 /PRNewswire/ — The new FDA cleared XO Score® system was successfully used to dilate multiple challenging fibrotic and calcific lesions in hemodialysis patients with stenotic and occluded fistulas. Dr. Richard Saxon, FSIR and member of […]
ZURICH, November 10, 2020 / PRNewswire / – Concept Medical Inc., a company focused on medical devices for drug delivery in vascular interventions, announced the enrollment of the first patient in the SirPAD clinical study ( Sir olimus in P eripheral A rtery D isease) (Sirolimus in peripheral arterial disease). The SirPAD is the first randomized controlled clinical trial and for all who […]
Twelve-Month Results Presented Today in Late-Breaking Trials Session at Vascular Interventional Advances (VIVA) Conference PARIS–(BUSINESS WIRE)–LimFlow SA, the pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD), today announced the presentation of 12-month data from the […]
Meta-analysis of two major randomized controlled trials (RCTs) show no difference in mortality between patients treated with the Philips Stellarex drug-coated balloon (DCB) and those treated with percutaneous angioplasty (PTA), the current standard of care Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced […]
Study finds 100 percent target lesion patency at 30 days; 90.9 percent of patients free from revascularization at 6 months EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that 6-month data from the AVESS […]
CARLSBAD, Calif.–(BUSINESS WIRE)–Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces a one-day DABRA Summit, during which participants will have the opportunity to provide input on the design features and enhancements for the Company’s next-generation DABRA […]
Disrupt PAD III is Largest Randomized Study of Complex Patients Typically Excluded from Clinical Trials SANTA CLARA, Calif., Nov. 07, 2020 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, reported today that investigators […]
SAN JOSE, Calif., Nov. 7, 2020 /PRNewswire/ — VIVA Physicians, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the final round of anticipated late-breaking clinical trial results presented at the VIVA20 virtual meeting. Below are highlights of today’s late-breaking clinical trial presentations: […]
